Ovarian Committee. Closed Trials Upfront Surgery vs Neoadjuvant Chemotherapy Patients closed / 550 Leading EORTC Participating NCIC CTG Presentation. - ppt download
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
IJGC on X: "#podcast: The DESKTOP III Trial with Philipp Harter This week, @pedroramirezMD is joined by Prof. Philipp Harter to discuss The DESKTOP III Trial. ♫https://t.co/CZQXdMT97W @_kem @IGCSociety @ESGO_society @OncoAlert @agz_eriksson #
When should Surgery be used for Recurrent Ovarian Carcinoma? - ScienceDirect
Shannon Westin, MD, MPH, FASCO on X: "Patient selection clearly matters - DESKTOP III used the AGO criteria, SOC-1 used iMODEL score - both have been validated to predict ability to achieve
DESKTOP III Lay Summary of results
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
REVEL Trial Design for metastatic NSCLC | CYRAMZA® (ramucirumab)
I've got my business data in the QB desktop 30-day trial. I needed to transfer that data to my QB online account but my 30-day trial ended which means no access. Help?
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:1402011
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:3272978
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Inizia la prova gratuita di Tableau: scarica la versione di prova qui
Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
Shannon Westin, MD, MPH, FASCO on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" /
Shannon Westin, MD, MPH, FASCO on X: "Patient selection clearly matters - DESKTOP III used the AGO criteria, SOC-1 used iMODEL score - both have been validated to predict ability to achieve
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Diapositiva 1
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology